- Home
- PYPD
PYPD
PolyPid Ltd.
as 11-15-2024 4:00pm EST
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
| Founded: | 2008 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 24.2M | IPO Year: | 2020 |
| Target Price: | $12.00 | AVG Volume (30 days): | 8.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.95 - $9.20 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PolyPid Ltd. News
PYPD Breaking Stock News: Dive into PYPD Ticker-Specific Updates for Smart Investing
GuruFocus.com
4 days ago
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
GlobeNewswire
5 days ago
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
11 days ago
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
GlobeNewswire
19 days ago
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
GuruFocus.com
25 days ago
Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd
GlobeNewswire
a month ago
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
GlobeNewswire
2 months ago
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
GlobeNewswire
2 months ago
PolyPid to Participate in Three Upcoming Fall Investor Conferences
Compare PYPD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PYPD PolyPid Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.